(Q41154163)

27 September 2017

title

Japanese and American reports of randomized trials: differences in the reporting of adverse effects (English)

1 reference

27 September 2017

Hayashi K

1

1 reference

27 September 2017

Walker AM

series ordinal

2

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 April 1996

1 reference

Contemporary Clinical Trials

27 September 2017

published in

1 reference

27 September 2017

volume

17

1 reference

27 September 2017

issue

2

1 reference

27 September 2017

page(s)

99-110

1 reference

Statistical problems in the reporting of clinical trials. A survey of three medical journals.

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Worldwide safety experience with diclofenac

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Efficacy of diclofenac in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Efficacy of diclofenac in osteoarthritis. Experience in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

International experiences with diclofenac in osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

International experience with diclofenac in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

HMG CoA reductase inhibitors. Current clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Simvastatin: the clinical profile

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Lovastatin and simvastatin prevention studies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

Publication bias in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

On authorship and acknowledgments

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2896%2980001-8

7 January 2021

10.1016/S0197-2456(96)80001-8

Identifiers

DOI

1 reference

27 September 2017

1 reference